.jpg?width=1000&height=562&name=New%20Approach%20Methodologies%20(NAMs).jpg)
.png?width=1280&height=720&name=hubspot_featured_image_1200x628%20(1).png)
Scaling iPSC Manufacturing: From Cell Line Development to Clinical-Production
Learn how to scale iPSC manufacturing from clinical cell line development and gene editing to GMP cell banking and bioreactor expansion.
27 August 2026
Empowering the Future of Gene Editing with StemEdit OC-1 Protein
Discover the innovative StemEdit OC-1 Protein, a generative AI-designed gene-editing enzyme that enhances genome engineering with improved safety and efficiency.
20 July 2026
Induced Pluripotent Stem Cells: History and A Look Back
Explore the fascinating history of induced pluripotent stem cells, from early research milestones to recent advancements in cellular reprogramming techniques.
16 July 2026
.png?width=756&height=425&name=hubspot_featured_image_1200x628%20(1).png)
AI-Designed CRISPR Enables Hypoimmune iPSC Engineering for Off-the-Shelf Cell Therapy
REPROCELL's StemEdit platform enables the creation of hypoimmune iPSCs for scalable off-the-shelf cell therapies, reducing immune rejection and enhancing patient access.
04 June 2026
What Are Off-Target Effects in Cellular Gene Editing? Risks, Detection, and Solutions
Explore off-target effects in gene editing, from CRISPR risks and AI-driven detection to genomic safety in iPSC therapies.
20 May 2026
5 Hard Truths About Bringing Stem Cell Therapies to the Clinic
Discover the essential truths behind developing clinical-grade stem cell therapies and learn how to navigate the complexities of GMP manufacturing successfully.
30 March 2026
REPROCELL Attends Japan-Maryland Night 2026
REPROCELL was honored to attend Japan-Maryland Night on Wednesday March 4th 2026 Maryland State, USA, hosted by the Embassy of Japan (in Washington DC).
06 March 2026
From StemRNA™ Clinical Seed Clone to GMP-Ready Cell Therapy Programs
Discover how REPROCELL’s StemRNA™ Clinical iPSC Seed Clones streamline the path to GMP-ready cell therapy, simplifying regulatory processes and enabling scalable, high-quality manufacturing.
27 February 2026
OpenCRISPR-1: The First AI-Designed CRISPR Editor for High-Precision Gene & Cell Therapy
Discover OpenCRISPR-1 — the first fully AI-designed CRISPR–Cas editor. Built by generative large language model, it enables high-efficiency, high-specificity genome and base editing in human cells. Ideal for cell therapy, stem-cell research, and advanced gene-editing workflows.
16 December 2025
iPSC-, MSC- and iMSC-Derived Exosome Therapeutics: The Cell-Free Future of Regenerative Medicine
Explore the future of regenerative medicine with iPSC-, MSC-, and iMSC-derived exosome therapeutics, focusing on their advantages, challenges, and clinical potential.
19 November 2025
Current Landscape of FDA Stem Cell Approvals and Trials 2023-2025
Discover the latest advancements and FDA approvals in stem cell therapies, including iPSC and MSC treatments, reshaping the 2023-2025 clinical landscape.
02 September 2025
Why Early Genetic Variant Detection in iPSC Cultures Is Critical for Safe and Regulatory-Compliant Cell Therapies
Explore the crucial role of early genetic variant detection in iPSC cultures for ensuring safe, effective, and regulatory-compliant cell therapies. Learn about risk profiling and REPROCELL’s solutions.
01 August 2025
Able Biott Single-use Bioreactors Enhance the Development of Disease Models and Cell Therapy
Discover how Able Biott single-use bioreactors enhance disease modeling and cell therapy development through scalable, efficient iPSC culture solutions.
03 July 2025
Why mRNA Reprogramming Is the Key to Safer and Faster iPSC Generation?
Discover how mRNA reprogramming enhances the safety, efficiency, and scalability of iPSC generation for therapeutic applications. Explore REPROCELL's innovative technologies and services.
10 June 2025
Breaking Barriers in Women’s Health: The World’s First Live Birth Using Fertilo
Discover how Gameto achieved the world’s first live birth using Fertilo, a revolutionary in vitro oocyte maturation technology. Learn about its stem cell-driven innovation and how it's transforming fertility care for women worldwide.
21 May 2025
Key Challenges in Clinical iPSC Applications: How REPROCELL Helps You Succeed
Overcome key challenges in clinical iPSC applications with REPROCELL's ethical sourcing, advanced reprogramming, and tailored solutions for reliable, scalable therapies.
12 May 2025
Epigenetic Modifications: Their Role in iPSC Reprogramming and Differentiation
Explore the critical role of epigenetic mechanisms like DNA methylation and histone modifications in iPSC reprogramming and differentiation. Learn how optimizing epigenetic stability enhances reprogramming efficiency, reduces variability, and ensures safer, more reliable iPSC applications for research and therapy.
02 May 2025
REPROCELL Connects with Maryland Governor Moore During His Japan Visit
Maryland Governor Moore strengthens biotech ties with Japan, highlighting REPROCELL's pivotal role in the Maryland-Kanagawa partnership during his trade mission.
22 April 2025
Exosomes from Stem Cells: iPSC vs. MSC-Derived Exosomes for Aesthetic and Regenerative Medicine
Discover how iPSC and MSC-derived exosomes revolutionize skin rejuvenation and anti-aging treatments in aesthetic medicine. Main Point Summary: The blog explores the potential of exosomes derived from induced pluripotent stem cells (iPSCs) and mesenchymal stem cells (MSCs) for skin rejuvenation and anti-aging treatments in aesthetic medicine, comparing their effectiveness, mechanisms, and applications.
14 April 2025
Can Stem Cells Revolutionize Sustainable Food Production?
Discover how stem cell technology is transforming sustainable food production, offering ethical and scalable alternatives to conventional meat, dairy, and seafood.
31 March 2025
Qkineʼs Animal-Free Growth Factors and Cytokines are ideal for Stem Cell Culture
Qkine's growth factors and cytokines are of exceptional bioactivity and purity - essential for maintaining and differentiating stem cell cultures.
07 March 2025
Prince George’s County Economic Development Corporation Visits REPROCELL USA
REPROCELL USA hosts Prince George's County Economic Development Corporation, showcasing their biotech services and highlighting the benefits of operating in PG County.
03 March 2025
The Therapeutic Advantage of Induced Pluripotent Stem Cells-Derived Mesenchymal Stem Cells (iMSCs)
Discover the clinical benefits and advancements of using induced pluripotent stem cells-derived mesenchymal stem cells (iMSCs) in regenerative medicine and therapeutic applications.
24 February 2025
From Fibroblasts to Cancer-Attacking Cells: Insights from Recent Research on Natural Killer Cells Derived from Clinical Grade iPSCs
Discover the differentiation potential of induced pluripotent stem cells (iPSC) to cytotoxic NK cells, including recent advancements in research and therapy.
16 October 2024
What you should know about the FDA’s Biological License Application Process
Learn about the FDA's Biological License Application process, including submission requirements, review phases, and expedited pathways for biologics approvals.
19 September 2024
REPROCELL USA Inaugurates New GMP Laboratory
May 15, 2024: REPROCELL USA inaugurated its new GMP BioManufacturing Lab. The facility enables hiPSC and hMSC generation in a contaminant-free environment.
07 June 2024
Harnessing the Power of Mesenchymal Stem Cells
Discover the groundbreaking potential of Mesenchymal Stem Cells (MSCs) in biomedical research and therapeutic development.
27 May 2024
Quality Control: What is really in your hiPSC culture?
Whatever the goals of your project, a robust QC testing protocol assessing sterility, pluripotency, and genetic abnormalities, while maintaining sample identity, is critical.
11 December 2023
Exploring CHIR99021: The Key to Stem Cell Research and Beyond
CHIR 99021 effects on Wnt/β-catenin pathway
20 November 2023
Editing B2M and CIITA to Create Hypoimmune Cell Lines for Cell Therapy
Gene editing is a viable approach for reducing immunogenicity of iPSC-derived therapeutic cells. The B2M and CIITA HLA-regulatory genes are good targets.
29 August 2023
Recombinant Human Laminins and their Use in Cell Culture
Discover the biological processes that laminin regulates. Learn more about the use of laminin in stem cell research and culture.
05 January 2023
REPROCELL’s Stemgent Brings mRNA Reprogramming to the Clinical Sector
Discover how REPROCELL has employed its StemRNA™ 4th Generation Reprogramming Technology to bring the power of mRNA reprogramming to the clinical sector.
14 October 2022
Everything you need to know about the REPROCELL iPSC Biobank
Interested in learning about our off-the-shelf iPSCs? Read our blog article and discover everything you need to know about the REPROCELL iPSC Biobank.
30 November 2021
How we established an in vitro Parkinson’s Disease model
Discover how to establish an in vitro Parkinson’s Disease model using iPSC-derived neurons - from patient screening to neuronal maturation.
24 November 2021
How digital droplet PCR can improve CRISPR gene editing (with examples)
Looking to understand how digital PCR can improve your genome editing projects? Learn how digital PCR can improve your CRISPR gene editing (with examples).
05 October 2021
What is digital droplet PCR and how can it improve stem cell therapies?
Discover the definition of digital droplet PCR and how can it improve the safety of your stem cell therapies.
13 September 2021
.jpg?width=756&height=425&name=17AUG21%20TEXELL%20GMP%20Safety%20Cabinet%20Action%20(002).jpg)
The ultimate guide to REPROCELL’s GMP iPSC manufacturing service
Find out everything you need to know about REPROCELL's clinical stem cell services in our ultimate guide to REPROCELL’s GMP iPSC manufacturing service.
09 September 2021
The ultimate guide to REPROCELL’s stem cell research services
Looking to outsource your stem cell research project? Discover everything you need to know in our ultimate guide to REPROCELL’s stem cell research services
16 August 2021
Will mRNA change medicine for good?
Find out if mRNA will change medicine for good. Read about the molecules rise to fame in 2020 and how it could be used to treat diseases such as cancer.
12 August 2021
Our top 10 stem cell culture products
Read our countdown of the op 10 stem cell culture products sold by REPROCELL as chosen by our customers.
02 July 2021
Protocol for immunocytochemistry of stem cells
Read our tried-and-tested protocol for immunocytochemistry of stem cells and optimize your antibody concentrations.
29 January 2021
Five reasons to choose StemRNA 3rd Gen Reprogramming Technology
Looking for a more efficient iPSC reprogramming kit? Discover five reasons you should choose StemRNA 3rd Gen Reprogramming Technology for iPSC generation.
04 December 2020
CRISPR-Cas9: Big Data, Precision Medicine and Universal Cell Therapy
Find out how CRISPR-Cas9 can enhance big data, precision medicine, and universal cell therapy on the REPROCELL blog.
13 April 2020
![How is Stemchymal® performing in Clinical Trials? [Infographic]](https://www.reprocell.com/hs-fs/hubfs/21JAN20%20Mesnchymal%20Stem%20Cells%20MSC-1.jpeg?width=756&height=425&name=21JAN20%20Mesnchymal%20Stem%20Cells%20MSC-1.jpeg)
How is Stemchymal® performing in Clinical Trials? [Infographic]
Wondering how is Stemchymal® performing in Clinical Trials? Discover the main findings from Stemchymal's clinical trials in our infographic.
16 March 2020
Three challenges facing the introduction of iPSC-derived therapies
Discover three of the main challenges facing the introduction of iPSC-derived therapies on the REPROCELL blog.
12 February 2020
Cost Effective, Lab-scale Spheroid Culture of iPSCs
Looking for cost effective, lab-scale, spheroid culture of iPSCs? Discover how the ABLE Bioreactor enables smarter cell production - no experience needed.
21 January 2020
Stem cells offer hope for sufferers of Spinocerebellar Ataxia
Discover how stem cell treatments can offer hope for sufferers of Spinocerebellar Ataxia (SCA).
08 November 2019
How to mass culture induced pluripotent stem cells (iPSCs) using the ABLE Bioreactor System
Discover how to mass culture induced pluripotent stem cells (iPSCs) in spheroids using the ABLE Bioreactor System.
30 October 2019
Which stem cell reprogramming technology should I use?
Wondering which stem cell reprogramming technology you should use for your iPSC project? Discover the pros and cons of RNA Reprogramming from REPROCELL.
17 October 2019
Pluripotent Potential for Clinical Application
Discover the potential of induced pluripotent stem cells (iPSCs) for clinical application on the REPROCELL blog.
25 July 2019
Stem Cells for Autism
Visit the REPROCELL blog and find out how stem cells could be used to treat autism in the future.
03 April 2019
Neurite Outgrowth Assays using StemRNA Neuro
Find out more about REPROCELL's neurite outgrowth assay that uses StemRNA Neuro cells.
20 March 2019
Using human iPSCs as an in vitro model for regenerative medicine and disease modelling
The conventional drug discovery pathway is a very inefficient process with the majority of candidate drugs not reaching the market due to safety and/or efficacy issues. But the use of iPSCs allows high throughput screening of therapies and disease-specific treatment using patient-specific models.
22 February 2019
Tissue Sourcing for the Development of iPSC-derived Disease Models
Looking to source primary tissues for iPSC generation? Find out more about tissue sourcing for the development of iPSC-derived disease models.
06 February 2019
Xeno-free culture of stem cells in NutriStem® hPSC XF medium
Find out more information about the xeno-free culture of stem cells using NutriStem® hPSC XF medium.
05 February 2018